3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
9
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Non-small Cell Lung Cancer Metastatic
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Melanoma
1
Lymphoma
1
Fallopian Tube Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Disease Progression
1
Diarrhea
1
Chondrosarcoma
1
Carcinoma, Squamous Cell
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Advanced Gastric Cancer
1
Advanced Cancer
1
Advanced Breast Cancer
1
Interventions
enzalutamide
2
pazopanib
1
capivasertib
1
Watchful Waiting
1
STA 9090
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiosurgery
1
Dutasteride
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma of the Prostate
×
capivasertib
×
Clear all
NCT02525068
2018-08-08
RE-AKT
Institute of Cancer Research, United Kingdom
Phase 2
Unknown
136 enrolled